Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1862 results
August 2023
-
Key Release
Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria
Ad hoc announcement pursuant to Art. 53 LR The Phase III REMIX-1 and REMIX-2 studies met all primary and secondary endpoints, showing rapid, clinically meaningful improvements across… -
Statement
European Commission (EC) adopts decision endorsing CHMP recommendation to revoke the conditional marketing authorization for Adakveo® (crizanlizumab)
July 2023
-
Press Release
Sandoz receives positive CHMP opinion for multiple sclerosis biosimilar natalizumab
If approved, will be first-of-a-kind biosimilar natalizumab in Europe, for use in all indications of reference biologic Positive CHMP opinion based on evidence from extensive analytical… -
Press Release
Sandoz announces plans to build a Biosimilar Technical Development Center in Slovenia to support future growth of biosimilar pipeline
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026New end-to-end drug substance and drug… -
Key Release
Novartis delivers strong sales growth, robust margin expansion and raises guidance. Announces USD 15 billion share buyback and Board endorses Sandoz spin-off¹˒²
Ad hoc announcement pursuant to Art. 53 LRQ2 sales grew +9% (cc3, +7% USD) with core operating income growing +17% (cc, +9% USD)Innovative Medicines (IM) sales grew +9% (cc, +7% USD) and core… -
Key Release
Novartis réalise une forte croissance de son chiffre d’affaires et de sa marge, relève ses prévisions et annonce un rachat d’actions d’USD 15 milliards¹; le Conseil d’administration approuve le spin-off de Sandoz²
Annonce événementielle au sens de l’art. 53 LRAu T2, hausse du chiffre d’affaires de +9% (tcc3, +7% USD) et du résultat opérationnel core de +17% (tcc, +9% USD)Innovative Medicines (IM): hausse du… -
Key Release
Novartis erzielt kräftige Umsatz- und Margensteigerungen und erhöht die Prognose. Aktienrückkaufprogramm von USD 15 Milliarden angekündigt; der Verwaltungsrat unterstützt den Spin-off von Sandoz¹˒²
Ad-hoc-Mitteilung gemäss Art. 53 KRDer Umsatz wuchs im zweiten Quartal um +9% (kWk3, +7% USD), und das operative Kernergebnis verbesserte sich um +17% (kWk, +9% USD)Innovative Medicines (IM… -
Press Release
Novartis builds on neuroscience pipeline and xRNA platform capabilities with acquisition of DTx Pharma
DTx Pharma is a preclinical stage biotechnology company that focuses on developing siRNA therapies for neuroscience indications, leveraging its proprietary fatty acid ligand-conjugated… -
Key Release
Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto® combination patent; maintains 2023 guidance and mid-term outlook
Ad hoc announcement pursuant to Art. 53 LR U.S. District Court for the District of Delaware ruled the Entresto (sacubitril / valsartan) ‘combination patent’ to be invalid Novartis will appeal… -
Press Release
Sandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation, marking Sandoz entrance into US immunology space
Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulationAs one of the only adalimumab HCF biosimilars…
June 2023
-
Press Release
Novartis publishes new five-year efficacy data on Kesimpta® (ofatumumab) for the treatment of relapsing multiple sclerosis
Continuous Kesimpta® (ofatumumab) treatment maintained profound suppression of MRI lesion activity and resulted in an increase in the number of patients with relapsing forms of multiple sclerosis (… -
Press Release
Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
Divested assets to include Xiidra®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential therapy for chronic ocular surface painDeal consistent with Novartis focused strategy of…